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Ferumoxytol for the treatment of iron 
deficiency and iron-deficiency anemia of 
pregnancy
Jesse Gerb, William Strauss, Richard Derman, Vanessa Short, Ben Mendelson,  
Huzefa Bahrain and Michael Auerbach
Abstract
Introduction: A litany of recent evidence supports the morbidity of intra-natal iron-deficiency 
anemia and its prodrome, iron deficiency. Oral iron administered during second and third 
trimesters does not get to the developing fetus if the mother is iron deficient. This is especially 
concerning as the rapidly developing fetal brain is in particular need of iron sufficiency. Intra-
natal iron deficiency is associated with autism, schizophrenia and abnormal brain structure. 
The obstetrical literature reports an unacceptably high incidence of gastrointestinal adverse 
events with oral iron. The time iron honored standard in the United States for intravenous iron 
replenishment in gravidas is iron sucrose. While safe and effective, four to seven visits are 
required to accomplish what newer formulations can achieve with one.
Methods: Ferumoxytol is a superparamagnetic iron oxide linked to polyglucose sorbitol 
carboxymethylether-binding elemental iron tightly allowing administration of complete 
replacement doses in 15–30 min. Herein, we report the results of 131 consecutive, non-
selected, iron-deficient second- and third-trimester pregnant women who received either 
510 mg of intravenous (IV) ferumoxytol twice or 1020 mg once.
Results: Hemoglobin and iron parameter increments were highly statistically significant. No 
adverse events were reported. We report how a single infusion is safe and effective as the 
same dose over two visits, saving an unnecessary visit and IV placement, while reducing cost.
Conclusion: Ferumoxytol represents an efficacious and safe method of administration of IV 
iron which improves convenience for patients and practitioners, and is cost saving due to 
fewer visits.
Keywords: intravenous iron, iron deficiency, pregnancy, total dose infusion
Received: 22 January 2021; revised manuscript accepted: 27 April 2021.
Plain language summary
One or two infusions of intravenous iron for iron deficiency or iron-deficiency anemia  
of pregnancy simplifies care
This study was conducted to highlight the inconvenience of multiple doses of IV iron and 
how administering the same dose in one or two infusions simplifies care. We report 
how a single infusion is as safe and effective as the same dose over two visits, saving an 
unnecessary visit and IV placement, while reducing cost. This study supports a growing 
body of evidence, to date, unreported, with ferumoxytol in pregnancy, reporting improved 
convenience and decreased costs with higher doses of IV iron in one or two visits.
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Introduction
The magnitude of morbidity of iron-deficiency 
anemia (IDA), and its prodrome iron deficiency, is 
becoming more and more apparent in pregnancy 
with a litany of high-quality publications in the 
recent literature. In a prospective study of 2400 
iron-deficient women supplemented with oral 
iron,1 mothers’ parameters improved; however, 
45% of the neonates were iron deficient, based on 
cord-blood ferritin concentrations. A more recent, 
particularly poignant report of a cohort of 532,232 
Swedish individuals2 testing the hypothesis that 
‘anemia diagnosed in mothers during pregnancy is 
associated with an increased risk of autism spec-
trum disorders,’ reported anemia at any time dur-
ing pregnancy was associated with a statistically 
significant risk. Among the multifactorial etiologies 
of anemia in pregnancy, iron deficiency is the over-
whelmingly most common. Supporting the urgency 
of addressing iron deficiency and consistent with 
the result of the Swedish study, a recent review in 
the American Journal of Obstetrics and Gynecology3 
noted that the rapidly developing fetal brain is at 
particular risk of iron deficiency, which can occur 
as a proximate result of maternal iron lack. This 
review cogently reported low maternal gestational 
iron intake is associated with autism, schizophre-
nia, and abnormal brain structure in the offspring 
with documented deficits which can be measured 
with validated tools of recognition memory, slower 
speed of processing and poorer bonding, which 
persist after postnatal iron repletion. These daunt-
ing observations stress the importance of intra-natal 
iron sufficiency in deference to postnatal repletion.
It is self-evident to write that treatment of iron 
deficiency of pregnancy is iron replacement. The 
frontline standard, oral iron, is inexpensive, widely 
available and in the non-gravid state, often effec-
tive when taken and tolerated. Sadly, this duet is 
the exception rather than the rule. A high-quality 
meta-analysis of 6831 patients, many of whom 
were pregnant, reported greater than 70% of those 
to whom oral iron was prescribed reported unac-
ceptable gastrointestinal perturbation,4 and the 
obstetrical literature has numerous reports of 
unacceptably high incidences of gastrointestinal 
side effects.5,6 These data have led to recommen-
dations that intravenous (IV), and not oral iron, 
be frontline therapy for gravidas in the second 
trimester, with hemoglobin concentrations 
<10.5 g/dl and for all anemic women in the third 
trimester.7,8 The recently revised United Kingdom 
guidelines are consistent with these recommenda-
tions9 (“IV iron should be considered from the 
second trimester onwards for women with con-
firmed IDA who are intolerant of, or do not 
response to, oral iron” (2B). IV iron should be 
considered for women who present after 34 weeks’ 
gestation with confirmed IDA and hemoglobin of 
<100 g/dl (1C).
Multiple formulations of IV iron are available for 
commercial use in North America, Europe, and 
Asia. Iron sucrose, the often standard formulation 
for iron repletion in pregnancy, is safe and effec-
tive. However, unlike newer formulations with car-
bohydrate shells which bind elemental iron more 
tightly, allowing complete replacement of iron 
deficits in 15–30 min, doses of iron sucrose exceed-
ing 200–250 mg are proscribed10 due to an unac-
ceptably high incidence of vasoactive reactions.
One of these newer formulations, ferumoxytol 
(Feraheme, AMAG Pharmaceuticals, Waltham, 
MA, USA) is a superparamagnetic iron-oxide 
compound linked to polyglucose sorbitol carboxy-
methylether.11 This complex carbohydrate coating 
binds elemental iron tightly, allowing administra-
tion of large doses in 15–30 min. Ferumoxytol was 
approved in the United States in 2009 for use in 
iron deficiency associated with chronic kidney dis-
ease. The original label allowed a single vial of 
510 mg in 17 ml, to be infused very rapidly in as 
fast as 17 s (1 ml/s). This approach was associated 
with an unacceptably high incidence of infusion 
reactions, likely due to complement activation by 
labile free iron.12,13 In 2015, the US Food and 
Drug Administration (FDA) issued a change in 
the label for administering ferumoxytol as a slower 
510 mg infusion over 15 min, with a second infu-
sion approximately 1 week later. To obtain a 
broader label, the manufacturer performed a dou-
ble-blind comparison of ferumoxytol with ferric 
carboxymaltose (another formulation which allows 
a large dose to be administered over a short period 
of time) in 1997 patients.14 Two vials (1020 mg) of 
ferumoxytol were compared with two vials 
(1500 mg) of ferric carboxymaltose administered 
according to FDA labeling, with safety as the pri-
mary endpoint. A blinded, independent safety 
monitoring board assessed all potential reports for 
toxicity–hypersensitivity reactions, including ana-
phylaxis or hypotension. No difference in adverse 
events was noted, nor was there a clinically signifi-
cant difference in change in hemoglobin 
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concentration at 5 weeks, despite the higher dose 
of ferric carboxymaltose. As a result, in February 
of 2018, ferumoxytol was granted a broad label for 
use in all causes of IDA after oral iron intolerance, 
or for those conditions in which oral iron is ineffec-
tive or harmful.
In 2017, we published the first prospective study 
of intravenous iron performed in the United 
States in 74 oral-iron-intolerant, iron-deficient 
second- and third-trimester gravidas.15 A highly 
statistically significant increase in hemoglobin 
concentration and iron parameters was reported, 
as well as a statistically significant increment in 
patient-reported outcomes using a Visual Linear 
Analog Scale analysis. The formulation and 
administration method used was 1000 mg of low-
molecular-weight iron dextran administered over 
1 h. No serious adverse events were observed, and 
the authors concluded that a total dose infusion 
of intravenous iron represented an improved 
method of iron repletion in pregnancy, and was 
safe, effective, associated with fewer side effects 
than oral iron, more convenient, and less expen-
sive than those formulations requiring multiple 
infusions. Subsequently, after thousands of infu-
sions of ferumoxytol administered in our practice 
as 510 mg in two intravenous infusions on differ-
ent days, according to the FDA label, the insur-
ance carriers of the bulk of our patient population 
were approached. We had previously published 
the safety, efficacy and felicitousness of a single 
1020 mg infusion of ferumoxytol given in 15 min16 
in a 60-patient pilot study, as well as an updated 
safety and efficacy analysis of our experience in 
184 consecutive, non-selected iron-deficient 
patients across a wide spectrum of disorders, who 
received 1020 mg of ferumoxytol as a single 
30 min infusion.17 Of these 184, 33 were pregnant 
and in the second or third trimester. In both 
series, no serious adverse events were observed, 
with an efficacy defined as ⩾1 g increment in 
hemoglobin concentration over a minimum of 
4 weeks that approached 100%. Since that publi-
cation, we have treated hundreds of pregnant 
women with a total dose infusion of 1020 mg fer-
umoxytol in 30 min without a single serious 
adverse event. Herein, we report the results of the 
first 131 consecutive, non-selected, iron-deficient 
gravidas referred to our practice for treatment of 
IDA of pregnancy, who received either a single 
1020 mg or two 510 mg infusions of ferumoxytol.
Methods
The electronic medical records of 131 consecu-
tive, non-selected pregnant women in the second 
or third trimester referred to a community hema-
tology practice for the evaluation and treatment 
of IDA were reviewed. The start date was chosen 
with the administration of the first total dose infu-
sion of 1020 mg ferumoxytol following the initial 
insurance approval, by Maryland Blue Cross Blue 
Shield CareFirst, for the total dose infusion. 
While off label, this method of administration is 
standard in our practice and all demographic data 
were redacted, such that institutional review 
board approval and informed consent was obvi-
ated. A secure patient portal website was utilized 
to access data. Baseline de-identified demo-
graphic information (age, week of gestation at 
time of treatment, gravidity, and parity) was 
obtained. Baseline laboratory data were obtained 
within 4–5 weeks of administration of ferumoxy-
tol, along with the ferumoxytol dosing regimen. 
Follow-up data consisted of hemoglobin concen-
tration and iron indices at approximately 4 weeks 
(window 3–5 weeks). Where available, pregnancy 
outcomes and neonatal statuses were obtained. 
Any, and all, adverse events, occurring during or 
immediately after administration of IV iron, as 
well as any reported in the following week were 
collected, including any treatment administered 
or pre-medication and resolution of the event.
Consecutive, non-selected pregnant women 
referred for treatment of IDA in the second or 
third trimester of pregnancy, received either two 
infusions of 510 mg of ferumoxytol over 15 min 
on separate days, 3–8 days apart (according to 
label), or 1020 mg as a single infusion over 30 min 
(as permitted by insurance). No pre-medication 
was administered, unless there was a history of 
multiple drug allergies or asthma (n = 4), in which 
case methylprednisolone and ranitidine were 
administered intravenously prior to the infusion. 
The decision to administer IV iron was made on 
the basis of a serum ferritin <30 ng/ml and/or a 
percent transferrin saturation (TSAT = serum 
iron/total iron-binding capacity)  <20% irrespec-
tive of hemoglobin concentration (although 
hemoglobin results were captured).
Participant demographic and pregnancy charac-
teristics, and baseline and follow-up laboratory 
values were described overall and within each 
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study group. Means and standard deviations were 
produced for continuous variables, and frequency 
counts and percentages were generated for 
describing variables that were dichotomous or 
polytomous in nature. The balance of characteris-
tics between the 510 mg and the 1020 mg groups 
were compared using two-sample t tests for con-
tinuous variables and chi-square or Fisher’s exact 
tests for categorical variables. Changes in labora-
tory values from baseline to follow up were calcu-
lated, and the mean change in values was 
compared using t tests.
Results
A total of 52 subjects received 1020 mg as a single 
30 min infusion, and 79 as 510 mg in two 15 min 
infusions on different days. Demographic and 
pregnancy characteristics of all subjects and by 
type of infusion (510 mg or 1020 mg) are found in 
Table 1. The mean age for all subjects was 
29.6 years with a range of 19–42 years. The mean 
gestational age was 29.4 weeks with a range of 
14–38 weeks. A total of 18 women were in the 
second trimester and 107 in the third. The mean 
gravidity was 3.1, with a range of 1–10 (Table 1).
The mean time to follow up following the initial 
infusion was 13.7 weeks (range 4–29 weeks). The 
mean change in hemoglobin from baseline to fol-
low up was 1.9 g/dl (p < 0.0001). A similar benefit 
was observed for both TSAT (mean change 
17.1%; p < 0.0001) and serum ferritin (mean 
change 113.3 ng/ml; p < 0.0001).
Baseline and follow-up lab values of all subjects 
and by type of infusion (510 mg or 1020 mg) are 
shown in Tables 2 and 3, respectively. The mean 
change in hemoglobin from baseline to follow up 
was 1.8 g/dl and 2.3 g/dl for the 510 mg and 
1020 mg groups, respectively (p = 0.80). The 
mean change in TSAT from baseline to follow up 
was 19.1% and 14.3% for the 510 mg and 
1020 mg groups, respectively (p = 0.30). The 
mean change in ferritin from baseline to follow up 
was 134.9 ng/ml and 79.2 ng/ml for the 510 mg 
and 1020 mg groups, respectively (p = 0.03). The 
mean change in mean corpuscular volume from 
Table 1. Demographic and pregnancy characteristics.
Total n = 131 510 mg n = 79 1020 mg n = 52 p valuea
Maternal age, years, mean (SD) 29.6 (5.8) 29.8 (5.8) 29.3 (5.9) 0.60
Gravida, mean (SD) 3.1 (1.7) 3.0 (1.6) 3.3 (1.9) 0.32
Gravida, n (%)
1 23 (18.4) 14 (18.7) 9 (18.0) 0.91
2 31 (24.8) 20 (26.7) 11 (22.0)
3 22 (17.6) 12 (16.0) 10 (20.0)
4+ 49 (39.2) 29 (38.7) 20 (40.0)
Parity, mean (SD) 1.2 (1.0) 1.2 (1.1) 1.1 (0.9) 0.59
Parity, n (%)
0 36 (29.0) 23 (31.1) 13 (26.0) 0.52
1 47 (37.9) 25 (33.8) 22 (44.0)
2+ 41 (33.1) 26 (35.1) 15 (30.0)
Gestational age at first treatment, 
weeks, mean (SD)
29.4 (5.7) 30.0 (5.3) 28.4 (6.1) 0.11
ap value from Chi-square test or t test of 510 mg versus 1020 mg.
SD, standard deviation.
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baseline to follow up was 1.8 fl and 5.2 fl for the 
510 mg and 1020 mg groups, respectively 
(p = 0.29).
Among all infusions of 1020 mg or 510 mg, minor 
infusion reactions were observed in 19, of which 
11 occurred with the 510 mg infusion, and 8 with 
the 1020 mg infusion (Table 4). These reactions 
consisted of pressure in the chest and/or back, 
facial flushing, or nasal congestion. All were self-
limited, resolved within minutes, and all but one 
(patient refused) received the planned dose. 
There were no serious adverse events, episodes of 
hypotension or hospitalizations. Prior to resump-
tion of the planned therapy, 16 women received 
methylprednisolone and either ranitidine or 
famotidine without recurrence of the reaction. 
For the 72 in whom post-partum data were avail-
able, none reported adverse events at delivery.
Discussion
Recently published evidence reports statistically 
significant increments in neurodevelopmental 
disorders in children born with iron deficiency 
compared with those sufficient. Failure to insure 
intra-natal iron sufficiency is associated with 
immediate18 and long-term deficits and with an 
increased risk of postnatal iron deficiency despite 
oral iron supplementation of the mother.19,20 
These data shift the emphasis on iron repletion to 
intra-natal iron sufficiency rather than post-natal 
repletion. Additionally, iron deficiency is associ-
ated with preterm labor, peripartum hemorrhage 
and a small but measurable increment in mater-
nal mortality. Oral iron, the current frontline 
therapy for iron deficiency of pregnancy is associ-
ated with gastrointestinal adverse events in the 
majority of women, with resultant poor adher-
ence, informing on a need for IV iron. While iron 
sucrose, the time-honored standard for IV iron 
repletion in pregnancy is effective and safe, four 
to seven visits, each requiring the placement of an 
IV access device, are required. Therefore, there is 
need to add to the armamentarium of IV iron for-
mulations that are more easily administered. In 
this report of 131 iron-deficient pregnant women 
with anemia, we report on the safety and efficacy 
of IV ferumoxytol, 79 of whom received two 
510 mg doses and 52, 1020 mg once. Efficacy was 
Table 2. Baseline hemoglobin and iron parameters.
Total n = 131 mean (SD) 510 mg n = 79 mean (SD) 1020 mg n = 52 mean (SD) p valuea
Hemoglobin, g/dl 10.0 (0.9) 10.0 (0.9) 9.9 (0.1) 0.76
Ferritin, ng/ml 17.2 (26.3) 18.9 (32.8) 14.6 (10.4) 0.28
TSAT, % 12.1 (7.1) 12.4 (6.7) 11.7 (7.7) 0.58
MCV, fl 81.6 (7.3) 82.3 (7.0) 80.7 (7.7) 0.24
ap value from t test of 510 mg versus 1020 mg.
MCV, mean corpuscular volume; SD, standard deviation; TSAT, transferrin saturation.
Table 3. Follow-up hemoglobin and iron parameters.
Total n = 75, mean (SD) 510 mg, n = 48 mean (SD) 1020 mg, n = 27, mean (SD) p valuea
Hemoglobin, g/dl 11.9 (1.2) 11.8 (1.4) 12.1 (0.9) 0.36
Ferritin, ng/ml 129.6 (110.1) 151.6 (114.2) 94.9 (95.4) 0.04
TSAT, % 29.2 (18.7) 31.7 (19.5) 25.1 (16.9) 0.16
MCV, fl 84.0 (12.5) 83.0 (14.9) 85.7 (6.5) 0.28
ap value from t test of 510 mg versus 1020 mg.
MCV, mean corpuscular volume; SD, standard deviation; TSAT, transferrin saturation.
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demonstrated by a mean hemoglobin increment 
of 1.9 g/dl (1.8 g/dl in the 510 mg given twice, and 
2.3 g/dl in the 1020 mg infused once, cohorts, 
respectively). No serious adverse events were 
observed.
Consistent with these data, is a prospective study 
of 60 oral-iron-intolerant patients who received 
1020 mg of ferumoxytol administered in 15 min.16 
The primary endpoint was safety and tolerability, 
with secondary endpoints, change in hemoglobin 
concentration and TSAT. No serious adverse 
events were observed. The mean increments at 
4 weeks and 8 weeks were 2.1 g/dl and 2.6 g/dl, 
respectively. In a retrospective analysis of 176 
consecutive, non-selected patients, 33 of whom 
were pregnant in the second and third trimester, 
all received 184 infusions of 1020 mg of ferumox-
ytol. No serious adverse events were observed.17
The approximate 2 g/dl increase in hemoglobin in 
this current series was comparable with the efficacy 
previously demonstrated with the 1020 mg admin-
istration,16,17 in populations with a diverse etiology 
of IDA, as well as what has been reported in the 
literature with the FDA-approved regimen of 
510 mg given twice.14,21,22 Likely of even greater 
interest to practitioners is the safety and tolerability 
Table 4. Adverse reactions for 510 mg and 1020 mg ferumoxytol infusions.
Subject Symptom
510 mg 1 Flushing and chest pain (infusion stopped) then restarted and 
completed; flushing, SOB (infusion stopped and then completed)
 2 Abdominal pain, headache, flush, chest tightness
 3 Nasal congestion 10 min after ferumoxytol
 4 Lightheadedness
 5 Chest pressure, SOB, flushing, back pain
 6 SOB and chest pressure
 7 Flushing, chest pressure; resolved with fluids
 8 Chest tightness
 9 Nausea and nasal congestion
 10 Facial itching
 11 Flushing and nausea
1020 mg 1 Lightheadedness
 2 Flushing, infusion stopped, restarted at slower rate; completed 
without further difficulty
 3 Tightness in chest and SOB
 4 Fatigue
 5 Flushing, nausea after ranitidine and methylprednisolone
 6 Facial flushing; subsided when infusion stopped
 7 Cough, scratchy throat
 8 Cough
Adverse reactions for 510 mg: n = 11; 1020 mg: n = 8.
SOB, shortness of breath.
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of ferumoxytol given during the second or third tri-
mester. Few adverse events, none serious, and all 
self-limited, occurred with either administration 
paradigm. This experience with the tolerability of 
ferumoxytol mirrors what we have noted with the 
use of several thousand doses of ferumoxytol in the 
authors’ practice, as well as with the several other 
IV iron formulations we have employed.
The preponderance of published evidence sup-
ports an increased use of IV iron for iron defi-
ciency of pregnancy. In this series of 131, we 
demonstrate the safety and efficacy of ferumox-
ytol in pregnancy. The ability to administer a 
full replacement dose of IV iron in 15–30 min, 
increases convenience to both practitioners 
and patients, decreases cost, and improves 
adherence.
Conflict of interest statement
Jesse Gerb, Vanessa Short, Ben Mendelson, and 
Huzefa Bahrain had no disclosures. William 
Strauss is a former employee of and consultant to 
AMAG Pharmaceuticals. Richard Derman is a 
consultant to AMAG Pharmaceuticals. Michael 
Auerbach received research funding from AMAG 
Pharmaceuticals, and contributed in educational, 
non-promotional programs for Pfizer and 
Pharmacosmos.
Funding
The authors received no financial support for the 
research, authorship, and/or publication of this 
article.
ORCID iD
Michael Auerbach  https://orcid.org/0000- 
0003-0707-8647
References
 1. Shao J, Lou J, Rao R, et al. Maternal serum 
ferritin concentration is positively associated with 
newborn iron stores in women with low ferritin 
status in late pregnancy. J Nutr 2012; 142: 
2004–2009.
 2. Wiegersma A, Dalman C, Lee B, et al. 
Association of prenatal maternal anemia with 
neurodevelopmental disorders. JAMA Psych 
2019; 76: 1294–1304.
 3. Georgieff M. Iron deficiency in pregnancy. Am J 
of Obstet Gynecol 2020; 223: 516–524.
 4. Tolkien Z, Stecher L, Mander A, et al. Ferrous 
sulfate supplementation causes significant 
gastrointestinal side-effects in adults: a systemic 
review and meta-analysis. PLoS One 2015; 10: 
e0117383.
 5. Van Wyck D, Martens M, Seid M, et al. 
Intravenous ferric carboxymaltose compared with 
oral iron in the treatment of postpartum anemia: 
a randomized controlled trial. Obstet Gynecol 
2007; 110: 267–278.
 6. Dhanani J, Ganguly B and Chauhan L. 
Comparison of efficacy and safety of two 
parenteral iron preparations in pregnant women. 
J Pharmacol Pharmacother 2012; 3: 314–319.
 7. Achebe M and Gafter-Gvili A. How I treat 
anemia in pregnancy: iron, cobalamine and folate. 
Blood 2017; 129: 940–949.
 8. Auerbach M, Gafter-Gvili A and Macdougall I. 
Intravenous iron: a framework for changing the 
management of iron deficiency. Lancet Haematol 
2020; 7: 342–350.
 9. Pavord S, Daru J, Prasannan N, et al. UK 
guidelines on the management of iron deficiency 
in pregnancy. Br J Haematol 2020; 188: 819–830.
 10. Chandler G, Harchowal J and Macdougall I. 
Intravenous iron sucrose: establishing a safe dose. 
Am J Kidney Dis 2001; 38: 988–991.
 11. Balakrishnan V, Rao M, Kausz, et al. 
Physiochemical properties of ferumoxytol, a new 
intravenous iron preparation. Er J Clin Invest 
2009; 39: 489–496.
 12. Macdougall I and Vernon K. Complement 
activation-related pseudo-allergy: a fresh look at 
hypersensitivity reactions to intravenous iron. Am 
J Nephrol 2017; 45: 60–62.
 13. Szebeni J, Fishbane S, Hedenus M, et 
al. Hypersensitivity to intravenous iron: 
classification, terminology, mechanisms and 
management. Br J Pharmacol 2015; 172:  
5025–5036.
 14. Adkinson N, Strauss W, Macdougall I, et al. 
Comparative safety of intravenous ferumoxytol 
versus ferric carboxymaltose in iron deficiency 
anemia: a randomized trial. Am J Hematol 2018; 
93: 683–690.
 15. Auerbach M, James S, Nicoletti M, et al. Results of 
the first American prospective study of intravenous 
iron in oral iron-intolerant iron-deficient gravidas. 
Am J Med 2017; 130: 1402–1407.
 16. Auerbach M, Strauss W, Rineer S, et al. Safety 
and efficacy of total dose infusion of 1020 mg of 
Therapeutic Advances in Hematology 12
8 journals.sagepub.com/home/tah
ferumoxytol administered over 15 minutes. Am J 
Hematol 2013; 88: 944–947.
 17. Karki N and Auerbach M. Single total dose 
infusion of ferumoxytol (1020 mg in 30 minutes) 
is an improved method of administration of 
intravenous iron. Am J Hematol 2019; 94: 
229–231.
 18. Siddappa A, Georgieff M, Wewerka S, et al. 
Auditory recognition memory in iron-deficient 
infants of diabetic mothers. Pediatr Res 2004; 55: 
1034–1041.
 19. Zhao G, Guobin X, Zhou M, et al. Prenatal 
iron supplementation reduces maternal anemia, 
iron deficiency, iron deficiency anemia in a 
randomized clinical trial in rural China, but iron 
deficiency remains widespread in mothers and 
neonates. J Nutr 2015; 145: 1916–1923.
 20. Georgieff M, Krebs N and Cusick S. The benefits 
and risks of iron supplementation in pregnancy 
and childhood. Ann Rev Nutr 2019; 39:121–146.
 21. Hetzel D, Strauss D, Bernard K, et al. A phase 
III, randomized, open-label trial of ferumoxytol 
compared with iron sucrose for the treatment of 
iron deficiency anemia in patients with a history 
of unsatisfactory oral iron therapy. Am J Hematol 
2014; 89: 646–650.
 22. Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and 
safety of IV ferumoxytol for adults with iron deficiency 
anemia previously unresponsive to or unable to 
tolerate oral iron Am J Hematol 2014; 89: 7–12.
Visit SAGE journals online 
journals.sagepub.com/
home/tah
SAGE journals
